+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Castleman Disease Treatment Market by Disease Type (Multicentric Castleman's Disease, Unicentric Castleman's Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Forecast 2024-2030- Product Image
Global Castleman Disease Treatment Market by Disease Type (Multicentric Castleman's Disease, Unicentric Castleman's Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Forecast 2024-2030- Product Image
Sale

Global Castleman Disease Treatment Market by Disease Type (Multicentric Castleman's Disease, Unicentric Castleman's Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336683
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023, USD 334.15 million in 2024, and is expected to grow at a CAGR of 13.62% to reach USD 719.87 million by 2030.

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Castleman Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Multicentric Castleman’s Disease
    • Unicentric Castleman’s Disease
  • Indication
    • Angiofollicular Lymph Node Hyperplasia
    • Angiomatous Lymphoid
    • Castleman Tumor
    • Giant Benign Lymphoma
    • Giant Lymph Node Hyperplasia
    • Hamartoma of the Lyphatics
  • Treatment
    • Antiviral Drugs
    • Chemotherapy
    • Corticosteroids
    • Immunotherapy
    • Monoclonal Antibodies
    • Radiation Therapy
  • Application
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Castleman Disease Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Castleman Disease Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?
  4. What is the market share of the leading vendors in the Castleman Disease Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Castleman Disease Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Castleman Disease Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
5.1.2. Restraints
5.1.2.1. Complexities in the drug development for Castleman disease
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
5.1.4. Challenges
5.1.4.1. Lack fo standardized treatment protocols
5.2. Market Segmentation Analysis
5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman’s disease due to the chances of systemic organ failure
5.2.2. Indication: Rising adoption of Castlemann’s disease treatment options for tackling angiomatous lymphoid cases
5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Castleman Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Multicentric Castleman’s Disease
6.3. Unicentric Castleman’s Disease
7. Castleman Disease Treatment Market, by Indication
7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics
8. Castleman Disease Treatment Market, by Treatment
8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy
9. Castleman Disease Treatment Market, by Application
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
10. Americas Castleman Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Castleman Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Castleman Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
13.3.2. Award, Recognition, & Expansion
13.3.2.1. FDA Approves Tocilizumab Biosimilar Tofidence
13.3.2.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Agilent Technologies, Inc.
14.1.3. Amgen Inc.
14.1.4. Artiva Biotherapeutics, Inc.
14.1.5. Bayer AG
14.1.6. Bio-Rad Laboratories, Inc.
14.1.7. Biogen Inc.
14.1.8. Boehringer Ingelheim GmbH
14.1.9. Bristol-Myers Squibb Company
14.1.10. Cadila Pharmaceuticals Limited
14.1.11. Celltrion Healthcare Co.,Ltd.
14.1.12. F. Hoffmann-La Roche AG
14.1.13. Gilead Sciences, Inc.
14.1.14. GlaxoSmithKline PLC
14.1.15. Glenmark Pharmaceuticals S.A.
14.1.16. Johnson & Johnson Services, Inc.
14.1.17. LGM Pharma
14.1.18. Merck & Co., Inc.
14.1.19. Novartis AG
14.1.20. Octapharma AG
14.1.21. Pfizer, Inc.
14.1.22. Recordati Group Company
14.1.23. Recordati S.p.A.
14.1.24. Sanofi S.A.
14.1.25. Sartorius AG
14.1.26. Sun Pharmaceutical Industries Ltd.
14.1.27. Takeda Pharmaceutical Company Limited
14.1.28. Teva Pharmaceutical Industries Ltd.
14.1.29. Thermo Fisher Scientific Inc.
14.1.30. Viatris Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 12. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 6. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 9. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 16. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 150. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 194. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 195. CASTLEMAN DISEASE TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Celltrion Healthcare Co.,Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals S.A.
  • Johnson & Johnson Services, Inc.
  • LGM Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer, Inc.
  • Recordati Group Company
  • Recordati S.p.A.
  • Sanofi S.A.
  • Sartorius AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 334.15 Million
Forecasted Market Value ( USD ) by 2030 $ 719.87 Million
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Castleman Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Castleman Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
Global Castleman Disease Treatment Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Castleman Disease Treatment Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 162 Pages
  • Global
From
idiopathic Multicentric Castleman's disease (iMCD) - Pipeline Insight, 2024 - Product Image

idiopathic Multicentric Castleman's disease (iMCD) - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Castleman Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Castleman Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 93 Pages
  • Global
From
Castleman Disease - Pipeline Insight, 2024 - Product Image

Castleman Disease - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From

About the Castleman Disease Drugs Market

Castleman Disease (CD) is a rare lymphoproliferative disorder that affects the lymph nodes and other organs. It is classified as a subtype of lymphoma, and is characterized by an overgrowth of lymphoid cells. Treatment for CD typically involves chemotherapy, radiation therapy, and/or immunosuppressive drugs. The Castleman Disease Drugs market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat CD, such as monoclonal antibodies, interferons, and corticosteroids. These drugs are used to reduce the size of lymph nodes, reduce inflammation, and suppress the immune system. Some companies in the Castleman Disease Drugs market include AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.